Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Gabriele De Luca MD, DPhil, FRCPath, FAAN

Gabriele C. De Luca MD, DPhil, FRCPath, FAAN

Professor of Clinical Neurology and Experimental Neuropathology, Neurodegeneration and Inflammation Research Group, Nuffield Department of Clinical Neurosciences; Director of Clinical Neurosciences Undergraduate Education, Oxford Medical School, University of Oxford, Oxford, United Kingdom

Gabriele De Luca is Professor of Clinical Neurology and Experimental Neuropathology, Honorary Consultant Neurologist, and Director of Clinical Neurosciences Undergraduate Education at the University of Oxford.

He has established an internationally recognised research group focused on the neuropathology of multiple sclerosis and other inflammatory and neurodegenerative diseases. His research work has resulted in numerous publications and awards, including the prestigious Cavanagh Prize awarded by the British Neuropathological Society and Fellowship of the Royal College of Pathologists.

He is the inaugural chair of Leadership University at the American Academy of Neurology, co-leads the MS Leadership Academy in the UK, and has been named an Oxford University Hospitals "Champion for Change."

Disclosures

Prof. De Luca has received support from the NIHR Biomedical Research Centre (BRC), Oxford, and research funding from the Oxford BRC, MRC(UK), UK MS Society, National Health and Medical Research (Australia), American Academy of Neurology, the Oxford-Quinnipiac Partnership, and Merck-Serono. He has received travel expenses from Bayer Schering, Biogen Idec, Genzyme, Merck Serono, Novartis, MS Academy, and American Academy of Neurology (AAN); and honoraria as an invited speaker/faculty for Novartis, Roche, Merck Serono, the MS Academy, and AAN.

Recent Contributions to PracticeUpdate:

  1. HLA-DRB1*1501 Influences Long-Term Disability Progression and Tissue Damage in Patients With Relapse-Onset MS

Most Read This Week

Recently Updated